Low-dose imipramine for refractory functional dyspepsia: A randomized, double-blind, placebo-controlled trial
The Lancet: Gastroenterology & Hepatology Dec 12, 2018
Cheong PK, et al. - The researchers assessed the safety and efficiency of imipramine, a tricyclic antidepressant (TCA), in the treatment of functional dyspepsia between Sept 11, 2005, and Aug 20, 2010, in 107 Helicobacter pylori-negative individuals. It was assumed that low-dose imipramine should be regarded as a possible medicine for subjects with functional dyspepsia not responding to proton pump inhibitors (PPIs) and prokinetics. Mild adverse effects eg, dry mouths, constipation, drowsiness, insomnia, palpitations, and blurred vision were also observed.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries